Solid Biosciences’ SWOT analysis: gene therapy stock poised for growth amid challenges

Investing.com. Published 07/29/2025 

SGT-212 for Friedreich’s Ataxia: Recently received FDA Investigational New Drug (IND) clearance Unique dual-route administration approach targeting both neurologic and cardiac manifestations Phase 1b dose-finding study set to begin in the second half of 2025